Resectable adenocarcinoma of the oesophagogastric junction care: Which perioperative treatment?;Prise en charge des adénocarcinomes de la jonction œsogastrique résécables : quel traitement périopératoire ?

Cancer/Radiotherapie

Volumn 12, Issue 5, 2008, Pages 365-373

  Crehange G ^a   Bonnetain, F ^a   Chauffert, B ^a   Rat, P ^b   Bedenne, L ^b   Maingon, P ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Adenocarcinoma; Cardia; Chemotherapy; Neoadjuvant; Oesophagus; Radiochemotherapy; Surgery

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; LOWER ESOPHAGUS SPHINCTER; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; POSTOPERATIVE CARE; PREOPERATIVE CARE; STOMACH NEOPLASMS;

EID: 50849096690     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2008.02.002     Document Type: Short Survey

References (59)

1. Adenis A., Mariette C., Mirabel X., Sarrazin T., Lartigau E., and Triboulet J.P. Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with oesophageal cancer. Early termination of a phase I trial. Eur J Surg Oncol 34 (2008) 30-35
2. Ban S., Michikawa Y., Ishikawa K., Sagara M., Watanabe K., Shimada Y., et al. Radiation sensitivities of 31 human oesophageal squamous cell carcinoma cell lines. Int J Exp Pathol 86 (2005) 231-240
3. Barbour A.P., Rizk N.P., Gonen M., Tang L., Bains M.S., Rusch V.W., et al. Adenocarcinoma of the gastro-oesophageal junction: influence of oesophageal resection margin and operative approach on outcome. Ann Surg 246 (2007) 1-8
4. Blot W.J., Devesa S.S., Kneller R.W., Fraumeni J.F., and Rising Jr. Incidence of adenocarcinoma of the oesophagus and gastric cardia. JAMA 265 (1991) 1287-1289
5. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouché O et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower oesophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S. Abst. 4510.
6. Bonenkamp J.J., Hermans J., Sasako M., van de Velde C.J., Welvaart K., Songun I., et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 340 (1999) 908-914
7. Burmeister B.H., Smithers M., Gebski V., Fitzgerald L., Simes R.J., Devitt P., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6 (2005) 659-668
8. Chapet O. Acute and late toxicities in thoracic irradiation. Cancer Radiother 11 (2007) 92-100
9. Chow W.H., Blot W.J., Vaughan T.L., Risch H.A., Gammon M.D., Stanford J.L., et al. Body mass index and risk of adenocarcinomas of the oesophagus and gastric cardia. J Natl Cancer Inst 90 (1998) 150-155 Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003; 39: 1603-9
10. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., et al. Perioperative chemotherapy versus surgery alone for resectable gastro-oesophageal cancer. N Engl J Med 355 (2006) 11-20
11. Cuschieri A., Weeden S., Fielding J., Bancewicz J., Craven J., Joypaul V., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79 (1999) 1522-1530
12. Engel L.S., Chow W.H., Vaughan T.L., Gammon M.D., Risch H.A., Stanford J.L., et al. Population attributable risks of oesophageal and gastric cancers. J Natl Cancer Inst 95 (2003) 1404-1413
13. Fuchs C, Tepper JE, Niedwiecki D, Hollis D, Haller DG, Dragovich T et al. Postoperative adjuvant chemoradiation for gastric or gastro-oesophageal adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): interim toxicity results from Intergroup trial CALGB 80101. ASCO Gastro-intest Cancer Symp, 2006: Abst no.61.
14. Gebski V., Burmeister B., Smithers B.M., Foo K., Zalcberg J., Simes J., and Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8 (2007) 226-234
15. Gunderson L.L. Gastric cancer - patterns of relapse after surgical resection. Semin Radiat Oncol 12 (2002) 150-161
16. Hallissey M.T., Dunn J.A., Ward L.C., and Allum W.H. The second British stomach cancer group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 343 (1994) 1309-1312
17. Hartgrink H.H., van de Velde C.J., Putter H., Bonenkamp J.J., Klein Kranenbarg E., Songun I., et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22 (2004) 2069-2077
18. Hölscher A.H., Bollschweiler E., Schneider P.M., and Siewert J.R. Prognosis of early oesophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer 76 (1995) 178-186
19. Hulscher J.B., Tijssen J.G., Obertop H., and van Lanschot J.J. Transthoracic versus transhiatal resection for carcinoma of the oesophagus: a meta-analysis. Ann Thorac Surg 72 (2001) 306-313
20. Hulscher J.B., van Sandick J.W., de Boer A.G., Wijnhoven B.P., Tijssen J.G., Fockens P., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the oesophagus. N Engl J Med 347 (2002) 1662-1669
21. Jenkins V.K., Barranco S.C., Townsend Jr. C.M., Perry R.R., and Ives K.L. Differential response to gamma radiation of human stomach cancer cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 50 (1986) 269-278
22. Kelsen D.P., Ginsberg R., Pajak T.F., Sheahan D.G., Gunderson L., Mortimer J., et al. Chemotherapy followed by surgery compared with surgery alone for localized oesophageal cancer. N Engl J Med 339 (1998) 1979-1984
23. Krasna M, Tepper JE, Niedzwiecki D, Hollis D, Reed C, Goldberg RM et al. Sugarbaker Jr, Mayer R. J. Trimodality therapy is superior to surgery alone in oesophageal cancer: results of CALGB 9781. ASCO Gastro-intest Cancer Symp, 2006: Abst no. 4.
24. Lauren P. The two histological main types of gastric carcinoma diffuse and so-called intestinal typre carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 64 (1965) 31-49
25. Lee H.K., Vaporciyan A.A., Cox J.D., Tucker S.L., Putnam Jr. J.B., Ajani J.A., et al. Postoperative pulmonary complications after preoperative chemoradiation for oesophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 57 (2003 Dec 1) 1317-1322
26. Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E., Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 1992;216:583-90.
27. Li H. Malignant Barrett's oesophagus. Eur J Cancer Prev 2 (1993) 47-52
28. Lieberman M.D., Shriver C.D., Bleckner S., and Burt M. Carcinoma of the oesophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg 109 (1995) 130-138
29. Lund O., Hasenkam J.M., Aagaard M.T., and Kimose H.H. Time-related changes in characteristics of prognostic significance in carcinomas of the oesophagus and cardia. Br J Surg 76 (1989) 1301-1307
30. Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastro-oesophageal junction. N Engl J Med 345 (2001) 725-730
31. Mariette C., Finzi L., Piessen G., Van Seuningen I., and Triboulet J.P. Oesophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg 29 (2005) 39-45
32. Marsman W.A., Tytgat G.N., ten Kate F.J., and van Lanschot J.J. Differences and similarities of adenocarcinomas of the oesophagus and oesophagogastric junction. J Surg Oncol 92 (2005) 160-168
33. Mayne S.T., and Navarro S.A. Diet, obesity and reflux in the etiology of adenocarcinomas of the oesophagus and gastric cardia in humans. J Nutr 132 (2002) 3467S-3470S
34. Mayne S.T., Risch H.A., Dubrow R., Chow W.H., Gammon M.D., Vaughan T.L., et al. Nutrient intake and risk of subtypes of oesophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 10 (2001) 1055-1062
35. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727-1733
36. Moghissi K., Sharpe D.A., and Pender D. Adenocarcinoma and Barrett's oesophagus. A clinicopathological study. Eur J Cardiothorac Surg 7 (1993) 126-131
37. National comprehensive cancer network cLinical practice guidelines in oncology, v.2.2007. Oesophageal Cancer, http://www.nccn.org/professionals/physician_gls/PDF/esophageal.pdf
38. Péra M. Epidemiology of oesophageal cancer, especially adenocarcinoma of the oesophagus and oesophagogastric junction. Recent results in cancer research. In: Lange J., and Siewert Jr. (Eds). Esophageal carcinoma: state of the art (2000), Springer-Verlag, Berlin 1-14
39. Rohatgi P.R., Swisher S.G., Correa A.M., Wu T.T., Liao Z., Komaki R., et al. Histologic subtypes as determinants of outcome in oesophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 106 (2006) 552-558
40. Sant M., Aareleid T., Berrino F., Bielska Lasota M., Carli P.M., Faivre J., et al., EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 14 (2003) v61-v118
41. Sasako M., Sano T., Yamamoto S., Sairenji M., Arai K., Kinoshita T., et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 7 (2006) 644-651
42. Sato S., Kajiyama Y., Sugano M., Iwanuma Y., Sonoue H., Matsumoto T., et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of oesophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 61 (2005 Jan 1) 203-211
43. Schneider B.J., and Urba S.G. Preoperative chemoradiation for the treatment of locoregional oesophageal cancer: the standard of care?. Semin Radiat Oncol 17 (2007) 45-52
44. Siewert J.R., Bartels H., and Stein H.J. Abdomino-right-thoracic oesophagectomy with intrathoracic anastomosis in Barrett's cancer. Chirurg 76 (2005) 588-594
45. Siewert J.R., Böttcher K., Stein H.J., and Roder J.D. Relevant prognostic factors in gastric cancer: 10-year results of the German gastric cancer Study. Ann Surg 228 (1998) 449-461
46. Siewert J.R., Feith M., and Stein H.J. Biologic and clinical variations of adenocarcinoma at the oesophagogastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 90 (2005) 139-146
47. Siewert J.R., and Ott K. Are squamous and adenocarcinomas of the oesophagus the same disease?. Semin Radiat Oncol 17 (2007) 38-44
48. Siewert J.R., Stein H.J., Feith M., Bruecher B.L., Bartels H., and Fink U. Histologic tumor type is an independent prognostic parameter in oesophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234 (2001) 360-367
49. Siewert J.R., and Stein H.J. Carcinoma of the gastro-oesophageal junction-classification, pathology and extent of resection. Dis Esophagus 9 (1996) 173-182
50. Smalley S, Benedetti J, Estes N, Haller DG, Ajani JA et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastro-oesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008). ASCO Gastro-intest Cancer Symp, 2004: Abst. No. 6.
51. Stahl M, Walz MK, Stuschke M, Lehmann N, Seegenschmiedt MH, Riera Knorrenschild J et al. Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced oesophagogastric adenocarcinomas: first results of a randomized phase III trial. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S, 2007: Abstract No: 4511.
52. Thirion PG, Michiels S, Le Maître A, Tierney J, on behalf of the MetaAnalysis of Chemotherapy in Esophagus Cancer Collaborative Group Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. Abst. 4512.
53. Triboulet J.P., and Mariette C. Oesophageal squamous cell carcinoma stade III. State of surgery after radiochemotherapy (RCT). Cancer Radiother 10 (2006) 456-461
54. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., and Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional oesophageal carcinoma. J Clin Oncol 19 (2001) 305-313
55. Vaughan T.L., Davis S., Kristal A., and Thomas D.B. Obesity, alcohol, and tobacco as risk factors for cancers of the oesophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 4 (1995) 85-92
56. Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W., Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003;39:1603-9.
57. von Rahden B.H., Stein H.J., Feith M., Becker K., and Siewert J.R. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the oesophagogastric junction. J Clin Oncol 23 (2005) 874-879
58. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., and Hennessy T.P. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
59. Wijnhoven B.P., Siersema P.D., Hop W.C., van Dekken H., Tilanus H.W., and Rotterdam Oesophageal Tumour Study Group. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Br J Surg 86 (1999) 529-535